Just a few days ago, we learned that Dendreon is looking to woo a buyer. The question now is whether the struggling drugmaker can find a suitor to take on its baggage.
Teleflex will snatch up Texas-based Vidacare for $262.5 million to add that company's inside-the-bone/vascular access devices to its own product roster.
The private equity firm Juniper has completed its $68.3 million purchase of Theragenics, a struggling Georgia maker of surgical tools and prostate cancer treatments.
Covidien is lightening its stake in the medical sealant market, agreeing to sell its Confluent Surgical product line to Integra LifeSciences for $235 million as it cuts costs and refocuses on high-growth spaces.
Dendreon is getting tired of soldiering on alone. As Bloomberg reports, the Seattle-based company is casting about for buyers as its prostate cancer treatment Provenge continues to lag--and Dendreon's stock lags along with it.
The EU on Friday recommended approval of Actelion's Opsumit, following FDA approval the week before, and by today the takeover talk was in full swing. With regulators giving thumbs up to a drug projected to be a blockbuster, analysts say any number of companies may want to do a deal and add the assured revenue to their own top lines.
ICU Medical is out of the running for a buyout, Bloomberg reports, giving up on a protracted process just as the company's founder and CEO steps down.
Drugmakers long ago went global, and now drug wholesalers see the need to follow the same strategy. Months after AmerisourceBergen hooked up with Walgreen's and Alliance Boots in Europe, McKesson has struck a $5.4 billion deal to buy struggling German wholesaler Celesio.
Looks like $3 billion-plus may have been a little too much to ask for Aptalis Pharma. After exploring a sale of the specialty drugmaker and finding no one to take the bait, private equity firm TPG has hired two banks for an IPO, Reuters sources say.
So is Roche going to do some rare disease deals or not? Rumors of a possible buyout of Alexion and BioMarin--alternatively dissed and touted--helped make this one of the big questions for deal watchers. Roche CEO Severin Schwan's answer can now be summarized in one word: Maybe.